OP Asset Management’s Amicus Therapeutics FOLD Stock Holding History

OP Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-69,554	Closed	-$990K	–	833
2025 Q4	$990K	Buy	69,554 +38,173	+122%	+$375K	0.01%	592
2025 Q3	$247K	Hold	31,381	–	–	﹤0.01%	725
2025 Q2	$180K	Buy	31,381 +9,766	+45%	+$63K	﹤0.01%	746
2025 Q1	$176K	Buy	+21,615	New	+$200K	﹤0.01%	758

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

OP Asset Management's FOLD Position: Q1 2026 in Review

OP Asset Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 69,554 shares — an estimated $990K sold.

OP Asset Management first reported a position in FOLD in Q1 2025 and held it in 4 quarters. The position peaked at $990K in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

OP Asset Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
OP Asset Management sold 69,554 Amicus Therapeutics shares in Q1 2026, an estimated $990K.
OP Asset Management first reported a position in Amicus Therapeutics in Q1 2025 and held it in 4 quarters.
OP Asset Management's Amicus Therapeutics position peaked at $990K in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on OP Asset Management's 13F filing for Q1 2026, filed 9 Apr 2026.